In melanoma, aberrant activation of the BRAF/MEK signaling pathway plays a pivotal role in tumor progression, with mutations in the BRAF kinase being present in approximately 50% of melanomas, leading to the constitutive activation of the MAPK/ERK pathway [10,11]. This evidence concerns the gene BRAF and neoplasm.